Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

被引：387

作者：

Shojaei, Farbod ^{[1
]}

机构：

[1] Pfizer La Jolla, Oncol Res Unit, San Diego, CA 92121 USA

来源：

CANCER LETTERS | 2012年 / 320卷 / 02期

关键词：

Tumor angiogenesis; VEGF; Anti-angiogenesis therapy; Drug resistance; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; PACLITAXEL PLUS BEVACIZUMAB; TUMOR VASCULATURE; COLORECTAL-CANCER; BREAST-CANCER; MOUSE MODEL; PHASE-II; VEGF; CELLS;

D O I：

10.1016/j.canlet.2012.03.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

It has been nearly 9 years since the FDA (Food and Drug Administration) approved the first anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other angiogenic inhibitors have since been approved or are in different stages of clinical trials. However, continued clinical and preclinical investigations have identified major drawbacks associated with the application of this class of agents, including inherent/acquired resistance and induction of tumor invasiveness. In addition, lack of thoroughly validated predictive biomarkers has been one of the major hurdles to stratify cancer patients and to monitor tumor progression and response to the therapy. Investigations in clinic and preclinical models have provided some molecular and cellular mechanisms for the above challenges. This review aims to provide a concise update from recent findings. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：130 / 137

页数：8

共 118 条

[1]

Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes [J].

Abu Lila, Amr S. ;

Ishida, Tatsuhiro ;

Kiwada, Hiroshi .

PHARMACEUTICAL RESEARCH, 2010, 27 (07) :1171-1183

[2]

Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model [J].

Abu Lila, Amr S. ;

Kizuki, Shinji ;

Doi, Yusuke ;

Suzuki, Takuya ;

Ishida, Tatsuhiro ;

Kiwada, Hiroshi .

JOURNAL OF CONTROLLED RELEASE, 2009, 137 (01) :8-14

[3]

VASCULAR REACTIONS OF NORMAL AND MALIGNANT TISSUES INVIVO .1. VASCULAR REACTIONS OF MICE TO WOUNDS AND TO NORMAL AND NEOPLASTIC TRANSPLANTS [J].

ALGIRE, GH ;

CHALKLEY, HW .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1945, 6 (01) :73-85

[4]

MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis [J].

Anand, Sudarshan ;

Majeti, Bharat K. ;

Acevedo, Lisette M. ;

Murphy, Eric A. ;

Mukthavaram, Rajesh ;

Scheppke, Lea ;

Huang, Miller ;

Shields, David J. ;

Lindquist, Jeffrey N. ;

Lapinski, Philip E. ;

King, Philip D. ;

Weis, Sara M. ;

Cheresh, David A. .

NATURE MEDICINE, 2010, 16 (08) :909-U109

[5]

Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature [J].

Backer, Marina V. ;

Hamby, Carl V. ;

Backer, Joseph M. .

TISSUE-SPECIFIC VASCULAR ENDOTHELIAL SIGNALS AND VECTOR TARGETING, PART A, 2009, 67 :1-27

[6]

Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VEGF fusion proteins [J].

Backer, MV ;

Backer, JM .

BIOCONJUGATE CHEMISTRY, 2001, 12 (06) :1066-1073

[7]

Barakat MR, 2009, EXPERT OPIN INV DRUG, V18, P637, DOI [10.1517/13543780902855316 , 10.1517/13543780902855316]

[8]

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[9]

Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[10]

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin [J].

Borsi, L ;

Balza, E ;

Bestagno, M ;

Castellani, P ;

Carnemolla, B ;

Biro, A ;

Leprini, A ;

Sepulveda, J ;

Burrone, O ;

Neri, D ;

Zardi, L .

INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (01) :75-85

← 1 2 3 4 5 6 7 8 9 10 →